PerformanceRiskValuationProfitabilityCashflowLiquidityESGRevenue & Geographic ExposureForecastFinancial GrowthIncome GrowthCashflow GrowthBalance Sheet Growth
Samsara Inc. (IOT)
33.600.80 (-2.33%)
33.44 - 34.57
31.40 - 61.90
7.61M / 5.95M (Avg.)
-152.73 | -0.22
Steady, sustainable growth is a hallmark of high-quality businesses. Value investors watch these metrics to confirm that the company's fundamental performance aligns with—or outpaces—its current market valuation.
5.95%
Revenue growth 1.25-1.5x CFLT's 4.12%. Bruce Berkowitz would check if differentiation or pricing power justifies outperformance.
6.67%
Gross profit growth above 1.5x CFLT's 3.03%. David Dodd would confirm if the company's business model is superior in terms of production costs or pricing.
-93.99%
Negative EBIT growth while CFLT is at 4.68%. Joel Greenblatt would demand a turnaround plan focusing on core profitability.
-80.62%
Negative operating income growth while CFLT is at 4.68%. Joel Greenblatt would press for urgent turnaround measures.
-97.47%
Both companies face declining net income. Martin Whitman would suspect external pressures or flawed business models in the space.
-101.01%
Both companies exhibit negative EPS growth. Martin Whitman would consider sector-wide issues or an unsustainable business environment.
-101.01%
Both face negative diluted EPS growth. Martin Whitman would suspect an industry or cyclical slump with heightened share issuance across the board.
0.72%
Share reduction more than 1.5x CFLT's 1.62%. David Dodd would see if the company is taking advantage of undervaluation to retire shares.
0.72%
Diluted share reduction more than 1.5x CFLT's 1.62%. David Dodd would validate if the company is aggressively retiring shares or limiting option exercises.
No Data
No Data available this quarter, please select a different quarter.
-2.32%
Negative OCF growth while CFLT is at 167.71%. Joel Greenblatt would demand a turnaround plan focusing on real cash generation.
-5.81%
Negative FCF growth while CFLT is at 161.02%. Joel Greenblatt would demand improved cost control or more strategic capex discipline.
71.47%
10Y revenue/share CAGR under 50% of CFLT's 244.52%. Michael Burry would suspect a lasting competitive disadvantage.
71.47%
5Y revenue/share CAGR under 50% of CFLT's 244.52%. Michael Burry would suspect a significant competitive gap or product weakness.
129.82%
3Y revenue/share CAGR above 1.5x CFLT's 65.14%. David Dodd would confirm if there's an emerging competitive moat driving recent gains.
158.19%
10Y OCF/share CAGR in line with CFLT's 155.49%. Walter Schloss would see both as similarly efficient over the decade.
158.19%
5Y OCF/share CAGR is similar to CFLT's 155.49%. Walter Schloss might see parallel cost profiles or expansions producing comparable cash flow.
196.37%
3Y OCF/share CAGR 1.25-1.5x CFLT's 144.14%. Bruce Berkowitz might see if strategic cost controls or product mix drove recent gains.
76.40%
Positive 10Y CAGR while CFLT is negative. John Neff might see a substantial advantage in bottom-line trajectory.
76.40%
Positive 5Y CAGR while CFLT is negative. John Neff might view this as a strong mid-term relative advantage.
72.16%
3Y net income/share CAGR above 1.5x CFLT's 43.18%. David Dodd would confirm the company’s short-term strategies outmatch the competitor significantly.
11.07%
Equity/share CAGR of 11.07% while CFLT is zero. Bruce Berkowitz might see a slight advantage that can compound significantly over 10 years.
11.07%
Equity/share CAGR of 11.07% while CFLT is zero. Bruce Berkowitz might see a minor advantage that could compound if the firm maintains positive net worth growth.
4.69%
3Y equity/share CAGR at 50-75% of CFLT's 8.89%. Martin Whitman sees a short-term lag in net worth creation vs. the competitor.
No Data
No Data available this quarter, please select a different quarter.
No Data
No Data available this quarter, please select a different quarter.
No Data
No Data available this quarter, please select a different quarter.
-7.50%
Firm’s AR is declining while CFLT shows 20.06%. Joel Greenblatt sees stronger working capital efficiency if sales hold up.
-2.65%
Inventory is declining while CFLT stands at 0.00%. Joel Greenblatt sees potential cost and margin benefits if sales hold up.
2.44%
Asset growth at 50-75% of CFLT's 4.40%. Martin Whitman questions if the firm is lagging expansions or if the competitor invests more aggressively.
4.71%
BV/share growth above 1.5x CFLT's 2.08%. David Dodd confirms if consistent profit retention or fewer write-downs yield faster equity creation.
2.27%
We have some new debt while CFLT reduces theirs. John Neff sees the competitor as more cautious unless our expansions pay off strongly.
13.60%
R&D growth drastically higher vs. CFLT's 3.78%. Michael Burry fears near-term margin erosion unless breakthroughs are imminent.
11.38%
We expand SG&A while CFLT cuts. John Neff might see the competitor as more cost-optimized unless we expect big payoffs from the overhead growth.